Dr. Alhoshani is a Pharmacist and Pharmacologist. He graduated from King Saud University with an undergraduate degree in Pharmacy (B. Pharm). Later, he earned his PhD in Pharmacological Sciences  from the University of California, Irvine. He has dedicated more than five years in molecular pharmacology, structural biology, and aptamer development at UCI (Irvine, CA, USA) under the supervision of Prof. Melanie Cocco. He contributed to understanding the rescue mechanism of stabilization of p53 protein “guardian of the genome”. He also extensively studied the Neurite Out Growth protein (NOGO) binding to the cell membrane and developed specific ssDNA (aptamer) to block its negative effect. In early 2015, he joined the Department of Pharmacology and Toxicology at King Saud University, Saudi Arabia. as a faculty member, where he started teaching and conducting his independent research.

  Dr. Alhoshani received his post doctorate fellowship training through multiple scientific visits to prestigious international universities and research institutes. His vast scientific accomplishments include being awarded the International Scientific Partnership Program with the University of Oxford, a Fulbright Scholar Award at the Bachman Research Institute of City of Hope in California, and the Asian University Alliance Scholar Award at the United Arab University, Emirates, UAE. Additionally, he has been funded multiple junior faculty grants, and been awarded more than 10 patents.

     As principal investigator, Dr. Alhoshani leads the Immunotherapy and Molecular Pharmacology Lab (IMP). The lab focuses on applying principles from molecular pharmacology to develop advanced biological and small molecule therapeutics for cancer and autoimmune disease. His research interest includes therapeutic strategies that use aptamers, vaccines, and metal-based molecules.